spacer
home > ebr > autumn 2009 > primum non nocere: first, do no harm
PUBLICATIONS

 

Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.

spacer

 
News and Press Releases

Cytel expansion unlocks innovative clinical development expertise for APAC biopharma sector

Waltham, MA, September 06, 2022 – Cytel Inc., a pioneer of adaptive clinical trial design and provider of advanced biometrics services, has expanded its operations into the Asia-Pacific region (APAC). This enables biotech and biopharma companies in APAC to have easier access to Cytel’s established biometrics and advanced statistical solutions. For more than 35 years, Cytel has pioneered innovative adaptive clinical trial designs and a suite of validated statistical and predictive software platforms. Cytel has also successfully supported sponsors in all aspects of innovative clinical trials, from statistical design to implementation and regulatory acceptance, helping them reduce costs, shorten timelines, and better unlock the value of their data.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement